[HTML][HTML] Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …
treatment protocols based on a single vascular complication are no longer suitable for the …
Update on the pathophysiology and medical treatment of peripheral artery disease
J Golledge - Nature reviews cardiology, 2022 - nature.com
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Rivaroxaban in peripheral artery disease after revascularization
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …
revascularization are at high risk for major adverse limb and cardiovascular events. The …
Advances in revascularization for peripheral artery disease: revascularization in PAD
JA Beckman, PA Schneider, MS Conte - Circulation research, 2021 - Am Heart Assoc
Effective revascularization of the patient with peripheral artery disease is about more than
the procedure. The approach to the patient with symptom-limiting intermittent claudication or …
the procedure. The approach to the patient with symptom-limiting intermittent claudication or …
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular …
V Aboyans, R Bauersachs, L Mazzolai… - European Heart …, 2021 - academic.oup.com
The aim of this collaborative document is to provide an update for clinicians on best
antithrombotic strategies in patients with aortic and/or peripheral arterial diseases …
antithrombotic strategies in patients with aortic and/or peripheral arterial diseases …
Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial
AS De Vriese, R Caluwé… - Journal of the …, 2021 - journals.lww.com
Background In patients with normal renal function or early stage CKD, the risk-benefit profile
of direct oral anticoagulants (DOACs) is superior to that of vitamin K antagonists (VKAs). In …
of direct oral anticoagulants (DOACs) is superior to that of vitamin K antagonists (VKAs). In …
Contemporary medical management of peripheral artery disease
MP Bonaca, NM Hamburg, MA Creager - Circulation research, 2021 - Am Heart Assoc
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …
[PDF][PDF] 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
M Brunström, M Burnier… - Journal of …, 2023 - docred-strapi-cms-prod.s3.sa-east-1 …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The …
Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …